Sofie   Report issue

For profit Phase 2 Phase 3
Founded: Culver City CA United States (2008)

Organization Overview

First Clinical Trial
2022
NCT05262855
First Marketed Drug
2015
ammonia n-13
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SOFIE | SOFIE INC

Active Ingredients

Marketed Drugs (3)

ammonia n-13 (2015)

fludeoxyglucose f-18 (2015)

sodium fluoride (18F) (2015)

Drugs in Phase 3 Trials (1)

Key: Sofie (0) Acquired (1)

choline c11 (choline c-11) (1 trial)

Drugs in Phase 2 Trials (2)

[f-18]fapi-74 (1 trial)

fapi-46 (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3